Biogen
Facility of the year: 2013 winners announced
February 4, 2013Manufacturing and Production Biogen, MedImmune, Merck, Novartis, Roche
Three US and three European manufacturing plants have been selected as category winners for the annual Facility of the Year …
Biogen inks $299m deal for rare genetic disorder drug
January 5, 2012Research and Development, Sales and Marketing Biogen, Isis Pharma
Biogen has signed a new deal with drug discovery firm Isis for its spinal muscular atrophy drug ISIS-SMNRx. Biogen will pay …
Biogen and Samsung invest $300m on joint biosimilars venture
December 8, 2011Manufacturing and Production Biogen, Samsung, biosimilars
Biogen Idec and Samsung will invest $300 million in a joint venture to develop biosimilars. Both firms will contribute a …
Biogen’s MS drug hits phase III targets
October 27, 2011Sales and Marketing BG-12, Biogen, MS
Biogen’s potential blockbuster MS drug BG-12 has met its primary endpoint in a late-stage trial. BG-12 (dimethyl fumarate) tablets …
New MS drug shows promise for Abbott
August 10, 2011Research and Development, Sales and Marketing Abbott, Avonex, Biogen, MS, gilenya
Biogen and Abbott’s multiple sclerosis drug daclizumab has performed well in a mid-stage trial, but two deaths marred the overall …
Biogen Idec buys neurodegenerative disease rights
December 21, 2010Research and Development Alzheimer's, Alzheimer's disease, Alzheimer’s, Alzheimer’s disease, Biogen, Biogen IDEC, Neurimmune, Parkinson's disease, Parkinson’s disease, amyotrophic lateral sclerosis, neurodegenerative diseases
Biogen Idec has acquired a subsidiary of Swiss biotech company Neurimmune, and the rights to three pre-clinical immunotherapy drugs. The …
Biogen set to axe 650 jobs and focus on neurology
November 4, 2010Research and Development, Sales and Marketing Biogen, Rituxan, job cuts, pharma jobs
Biogen Idec is set to cut hundreds of jobs and refocus its R&D in an effort to cut costs by …
George Scangos to head up Biogen
July 7, 2010Research and Development Biogen, appointment, research and development
Biogen Idec has appointed George Scangos chief executive officer, with effect from 15 July. Scangos will join the company from …
Abbott starts head-to-head MS trial
May 25, 2010Research and Development, Sales and Marketing Abbott, Avonex, Biogen, Gilena, daclizumab
Abbott has started enrolment for a phase III trial of daclizumab, a once-monthly injection for relapsing-remitting multiple sclerosis that it …
Awards recognise top pharma manufacturing projects
January 19, 2010Manufacturing and Production Biogen, Genentech, Mannkind, Pfizer
The winners of the 2010 Facility of the Year Awards have been made public, with Pfizer grabbing two out of …
Biogen submits Fampridine PR to European regulators
January 14, 2010Sales and Marketing Biogen, Fampridine, MS
Biogen Idec is seeking European approval for a drug which helps multiple sclerosis sufferers to walk better. A marketing authorisation …
Mixed news for Biogen Idec on Tysabri
April 27, 2009Manufacturing and Production Biogen
Biogen Idec has won approval for a new high-titre manufacturing process for its multiple sclerosis product Tysabri (natalizumab) which should …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
